Genmab — Februar 2020
-
-
Ny ATH
-
-
2000.....here we come..:-D
-
Organ responses with daratumumab therapy in previously treated AL amyloidosis https://ashpublications.org/bloodadvances/article/4/3/458/440994/Organ-responses-with-daratumumab-therapy-in
-
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab https://clinicaltrials.gov/ct2/show/NCT04264884?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody&lupd_s=02%2F11%2F2020&draw=2&rank=1
-
-
Konklusionen fra 10:33 (thanks EL) kan godt tåle at blive vist her: "our study demonstrates that daratumumab-based therapy is a very effective treatment option for previously treated AL amyloidosis. In addition to producing deep hematologic responses, significant improvements in cardiac and renal organ responses can be observed, potentially translating into reduced morbidity and mortality."
-
Vi satte ny ATH i dag.:-)
-
Med meget tålmodige festdeltagere.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind